In a recent development, Sir Marc Feldmann, Ph.D., has resigned from his position on the Board of Directors of 180 Life Sciences Corp (NASDAQ:ATNF), a biotechnology company focused on the development of novel therapies for inflammatory diseases, fibrosis, and pain. The resignation took effect immediately on Tuesday.
Sir Feldmann, a renowned immunologist and academic, provided his notice of resignation to the company's board on the same day. According to the statement released by 180 Life Sciences, there were no disagreements between Sir Feldmann and the company that prompted his departure. The company's operations, policies, and practices have not been cited as factors in the decision.
The announcement was made public through a filing with the Securities and Exchange Commission (SEC). The filing did not elaborate on the reasons behind Sir Feldmann's resignation or indicate any immediate plans for a replacement on the Board of Directors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.